Immunovant Inc
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
16.7
1.2
(7.742%)
Volume:
974,830
52 week range:
3.15 - 20.24
Market Cap:
2.175B
Company Description:
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.